MedTrace Logo

A Phase 1 Study of FXR0906 in Healthy Adults With or Without Elevated Triglycerides

NCT07766759 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-08-14

No results posted yet for this study

Summary

This is a phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics effects of a single dose of FXR0906 injection or placebo in Chinese healthy adult volunteers with or without TG increase.

Conditions

  • Healthy Adult Volunteers

Interventions

DRUG

Intervention1: FXR0906 injection

A single dose of FXR0906 (dose 1 ) will be administered on Day 1 by subcutaneous injection

DRUG

Intervention2: FXR0906 injection

A single dose of FXR0906 (dose 2) will be administered on Day 1 by subcutaneous injection

DRUG

Placebo

the volume mached placebo is normal saline (0.9%) and will be administered on Day 1.

Sponsors & Collaborators

  • Fosun Pharmaceutical Industrial Development (Shenzhen) Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-08-25
Primary Completion
2027-09-24
Completion
2027-12-20
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07766759 on ClinicalTrials.gov